Phathom Pharmaceuticals Inc
NASDAQ:PHAT
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.21
19.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Phathom Pharmaceuticals Inc
Wall Street
Price Targets
PHAT Price Targets Summary
Phathom Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
PHAT
is 25.79 USD
with a low forecast of 18.18 USD and a high forecast of 29.4 USD.
PHAT Last Price Targets
Phathom Pharmaceuticals Inc
The latest public price target was made on Aug 8, 2024 by
Paul Choi
from
Goldman Sachs
,
who expects
PHAT
stock to
rise by 28%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Paul Choi
Goldman Sachs
|
12
USD
Upside 28% |
3 months ago
Aug 8, 2024
|
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
StreetInsider
|
|
Matthew Caufield
H.C. Wainwright
|
28
USD
Upside 200% |
4 months ago
Jul 19, 2024
|
H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
StreetInsider
|
Annabel Samimy
Stifel Nicolaus
|
24
USD
Upside 157% |
6 months ago
May 2, 2024
|
Phathom Pharmaceuticals initiated with a Buy at Stifel
TheFly
|
Joseph Stringer
Needham
|
26
USD
Upside 178% |
10 months ago
Jan 5, 2024
|
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PHAT's stock price target?
Price Target
25.79
USD
According to Wall Street analysts, the average 1-year price target for
PHAT
is 25.79 USD
with a low forecast of 18.18 USD and a high forecast of 29.4 USD.
What is Phathom Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
734%
The
compound annual growth rate
of Phathom Pharmaceuticals Inc's revenue for the next 3 years is
734%.
You don't have any saved screeners yet
